生物活性 | |||
---|---|---|---|
描述 | Clarithromycin exhibits a wide range of antimicrobial effects and is known for its capability to inhibit the CYP3A4 enzyme, which catalyzes the alpha-hydroxylation of triazolam, demonstrating an IC50 (Ki) value of 56 (43) µM[1]. This antibiotic also significantly blocks the HERG potassium current in a concentration-dependent manner, with an IC50 of 45.7 µM[2]. Clarithromycin impacts autophagic flux by disrupting the signaling pathway that connects hERG1 and PI3K[3]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01159574 | Multiple Myeloma | Phase 2 | Active, not recruiting | June 2020 | United States, New York ... 展开 >> Weill Cornell Medical College New York, New York, United States, 10065 收起 << |
NCT03487562 | Healthy | Phase 1 | Recruiting | August 29, 2018 | Korea, Republic of ... 展开 >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: In-Jin Jang, MD, PhD 82-2-2072-1666 ijjang@snu.ac.kr Principal Investigator: In-Jin Jang, MD, PhD 收起 << |
NCT01559935 | - | Active, not recruiting | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.34mL 0.27mL 0.13mL |
6.68mL 1.34mL 0.67mL |
13.37mL 2.67mL 1.34mL |
参考文献 |
---|